In addition, combination therapy with TGFB and ICIs is in the clinical drug development stage for hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer (NCT02423343; NCT02734160) (43). The gene discussed is TGFB1; the disease is hepatocellular carcinoma.